Compounds > rosiglitazone

Page last updated: 2024-08-25

rosiglitazone and Glioma

rosiglitazone has been researched along with Glioma in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (50.00)	29.6817
2010's	2 (33.33)	24.3611
2020's	1 (16.67)	2.80

Authors

Authors	Studies
Bronfman, M; Leisewitz, AV; Loyola, G; Martinez, GR; Urrutia, CR	1
Jan, HJ; Lai, JH; Lee, CC; Lee, HM; Lin, YM; Wei, HW	1
Alshekhlee, A; Barnholtz-Sloan, JS; Conway, DS; Grommes, C	1
Hao, X; Li, W; Ren, X; Wang, P; Yin, Q; Yu, J	1
Jang, KY; Jang, YB; Kang, KP; Kim, DH; Kim, W; Lee, JE; Lee, S; Moon, SO; Park, SK; Sung, MJ	1
Arora, A; Arya, MB; Bhatt, AN; Dwarakanath, BS; Parmar, VS; Prasad, AK; Verma, A	1

Other Studies

6 other study(ies) available for rosiglitazone and Glioma

Article	Year
A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis. Journal of cellular physiology, 2008, Volume: 217, Issue:2 Topics: Alkyl and Aryl Transferases; Animals; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Enzyme Induction; Glioma; Lipid Metabolism; Mice; Myelin Sheath; Oligodendroglia; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; PPAR-beta; Pyrimidines; Rats; Receptor Cross-Talk; RNA Interference; RNA, Small Interfering; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription, Genetic; Transfection	2008
Rosiglitazone reduces cell invasiveness by inducing MKP-1 in human U87MG glioma cells. Cancer letters, 2009, May-18, Volume: 277, Issue:2 Topics: Cell Line, Tumor; Dual Specificity Phosphatase 1; Glioma; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Neoplasm Invasiveness; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones	2009
Inverse association of PPARγ agonists use and high grade glioma development. Journal of neuro-oncology, 2010, Volume: 100, Issue:2 Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Pioglitazone; PPAR gamma; Retrospective Studies; Rosiglitazone; Thiazolidinediones	2010
Rosiglitazone suppresses glioma cell growth and cell cycle by blocking the transforming growth factor-beta mediated pathway. Neurochemical research, 2012, Volume: 37, Issue:10 Topics: Blotting, Western; Cell Cycle; Cell Division; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Glioma; Humans; Phosphorylation; Rosiglitazone; Smad3 Protein; Thiazolidinediones; Transforming Growth Factor beta	2012
Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:8 Topics: Anilides; Animals; Apoptosis; C-Peptide; Cell Line; Chromans; Cisplatin; Drug Evaluation, Preclinical; Glioma; Humans; Hypoglycemic Agents; Inflammation; Insulin; Intercellular Adhesion Molecule-1; Kidney; Kidney Diseases; Kidney Function Tests; Kidney Tubules, Proximal; Macrophages; Male; Mice; Mice, Inbred C57BL; Monocytes; PPAR gamma; Prostaglandin D2; Protein Transport; Rosiglitazone; Thiazolidinediones; Transcription Factor RelA; Troglitazone; Tumor Necrosis Factor-alpha	2006
Radiosensitization of calreticulin-overexpressing human glioma cell line by the polyphenolic acetate 7, 8-diacetoxy-4-methylcoumarin. Cancer reports (Hoboken, N.J.), 2022, Volume: 5, Issue:12 Topics: Acetates; Calreticulin; Cell Line; Coumarins; Glioma; Humans; Polyphenols; Radiation Tolerance; Radiation-Sensitizing Agents	2022